Vigil Neuroscience

Vigil Neuroscience

Edit info

  • Founded: 2020
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: ALSP
  • Drug types: NEU, RAR, GEN
  • Lead product: VGL101
  • Funding: $98M IPO Jan 2022; $90M B Aug 2021; $50M A Dec 2020


vigilneuro.com

linkedin.com

job board


Drug notes:

Also Clin0 other leukodystrophies; undisclosed Clin0 Alzheimer's

About:

Vigil Neuroscience is specializing in developing transformative medicines for neurological disorders, particularly Alzheimer's disease and other neurodegenerative conditions. Their scientific approach centers on microglia, the immune cells of the brain, to develop innovative therapeutics. Microglia become dysfunctional in neurodegenerative diseases. Thus, Vigil Neuroscience integrates cutting-edge neuroscience research with advanced drug discovery technologies to identify treatments that can selectively target microglia and restore brain homeostasis. Through their commitment to scientific rigor and clinical translation, Vigil Neuroscience aims to advance the understanding and treatment of neurological disorders, potentially offering new hope to patients and caregivers worldwide.

Jobs:

Vigil Neuroscience
Senior Manager / Associate Director, Contracts
Greater Boston Area, MA|11 days ago
Apply
Vigil Neuroscience
VP, Clinical & Medical Sciences (MD)
Greater Boston Area, MA|11 days ago
Vigil Neuroscience
Senior Director, Biostatistics
Watertown, MA|54 days ago


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com